HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Neuromyelitis optica — Clinical Guidelines

Overview

Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune condition affecting the central nervous system, characterized by demyelinating lesions and astrocytic damage, often initially misdiagnosed as multiple sclerosis. The presence of aquaporin-4 antibodies (AQP4-IgG) aids in accurate diagnosis and guides targeted therapeutic approaches 1 3.

Diagnosis

Key Diagnostic Criteria: Utilize the 2015 International Panel for NMO Diagnosis (IPND) criteria 1.

Recommended Tests: Perform AQP4-IgG testing via cell-based assays for confirmation 1.

Differential Diagnosis: Consider multiple sclerosis, myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and acute disseminated encephalomyelitis (ADEM) 1.

Serological and Imaging: Emphasize serological testing and neuroimaging for accurate diagnosis 3.

Diencephalic Involvement: Monitor for rare symptoms indicative of diencephalic involvement, such as narcolepsy, hypotension, amenorrhea, and syndrome of inappropriate antidiuretic hormone secretion 5.

Management

Acute Treatment: Initiate high-dose intravenous methylprednisolone promptly 1.

Steroid-Refractory Attacks: Early use of plasma exchange for severe or steroid-refractory attacks 1.

Long-Term Immunotherapy: Employ monoclonal antibodies including rituximab, inebilizumab, eculizumab, ravulizumab, and satralizumab 1.

Safety Considerations: Monitor for infections, particularly atypical mycobacterial infections, pneumococcal pneumonia, and pyelonephritis, in patients treated with satralizumab 2.

Special Populations

Pregnancy: Specific therapeutic management strategies for pregnant women with NMOSD are discussed, emphasizing careful monitoring and individualized treatment plans 3.

Key Recommendations

Diagnose NMOSD using the 2015 IPND criteria and confirm with AQP4-IgG testing via cell-based assays (Evidence: Strong 1).

Initiate high-dose intravenous methylprednisolone for acute attacks and consider plasma exchange for severe cases (Evidence: Moderate 1).

Use monoclonal antibodies such as rituximab or satralizumab for long-term immunosuppression (Evidence: Moderate 1 2).

Monitor for severe adverse events, especially infections, in patients treated with satralizumab (Evidence: Weak 2).

Develop individualized treatment plans for pregnant women with NMOSD (Evidence: Expert opinion 3).

References

1 Yamout B, Gouider R, Al-Roughani R, Aljarallah S, Shalaby N, Al-Khabouri J et al.. Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines. CNS drugs 2026. link 2 Zhang X, Xiong X, Wei J, Yan Y, Huang T. Real-world safety of satralizumab in neuromyelitis optica spectrum disorder: a FAERS-based risk stratification study. Journal of neurology 2026. link 3 Zakrzewska-Pniewska B, Bartosik-Psujek H, Brola W, Gołębiowski M, Kalinowska A, Kułakowska A et al.. Update on diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - recommendations of Section of Multiple Sclerosis and Neuroimmunology of Polish Neurological Society. Neurologia i neurochirurgia polska 2025. link 4 Bagherieh S, Afshari-Safavi A, Vaheb S, Kiani M, Ghaffary EM, Barzegar M et al.. Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): a systematic review and meta-analysis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2023. link 5 Etemadifar M, Nouri H, Khorvash R, Salari M, Ghafari K, Aghababaee A. Frequency of diencephalic syndrome in NMOSD. Acta neurologica Belgica 2022. link 6 Jones MV, Fox-Talbot K, Levy M. Evidence for classic complement activity in neuromyelitis optica. Clinical neuropathology 2014. link 7 Giovannoni G. Neuromyelitis optica and anti-aquaporin-4 antibodies: widening the clinical phenotype. Journal of neurology, neurosurgery, and psychiatry 2006. link 8 Misra R, Bajaj S. Neuromyelitis optica: a case report from India. Tropical and geographical medicine 1986. link 9 Khan MI. Neuromyelitis optica (relapsing type). JPMA. The Journal of the Pakistan Medical Association 1976. link 10 Williamson PM. Neuromyelitis optica following infectious mononucleosis. Proceedings of the Australian Association of Neurologists 1975. link

Neuromyelitis optica